Don’t miss – Page 212 – Endpoints News

SIGN UP

Merck's Roger Perlmutter pays $300M to scoop up a battered Immune Design for its I/O work

5 years ago

FDA cites an ‘ongoing review’ for Pfizer's blockbuster Xeljanz, with implications for the class

5 years ago

Pfizer drops 10 mg dose of best-selling Xeljanz as study spotlights cardio safety issue, higher rate of deaths

5 years ago

Intercept scores a mixed win on NASH Phase III sweepstakes, plans marketing pitch

5 years ago

The top 10 pipeline blowups, setbacks and snafus for H2 2018

5 years ago

AstraZeneca sweeps away the MedImmune name as CEO Soriot restructures R&D

5 years ago

Vas Narasimhan earned a big pay hike when he moved to the CEO's suite at Novartis

5 years ago

It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial

5 years ago

AbbVie jumps into the frenzied race for a BCMA/CD3 bispecific targeting multiple myeloma. Teneobio who?

5 years ago

Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today

5 years ago

Sangamo shares take a big hit as investors react to setback for pioneering gene-editing tech

5 years ago

Basking in praise and a $4.2B GSK pact, Merck KGaA blueprints expansion plans for Boston-area R&D campus

5 years ago

After Tesaro buy, GSK wades deeper into cancer unveiling big immunotherapy deal with Germany's Merck

5 years ago

Gilead takes an $820M hit after axing a Kite CAR-T. Are billions more going to be incinerated?

5 years ago

'Most feared' activist investor in America has zeroed in on Bristol-Myers Squibb. Is he planning to derail the $74B Celgene buyout?

5 years ago

Pharma, we have a problem: New drugs can't cover the cost of Big Pharma's failures

5 years ago

Playing hardball, Bristol-Myers bought out a battered Celgene with last-minute terms sweetened in its own favor

5 years ago

‘Can we stop that work, can we delay that work?’ Bristol-Myers’ top execs outline their game plan for absorbing Celgene

5 years ago

That biotech unicorn you (pick love or hate) just spotlighted some intriguing mouse (yes) data on a triple mRNA cancer therapy

5 years ago

Roche pulls another major piece out of the wobbly Alzheimer's jenga, shuttering crenezumab PhIIIs

5 years ago

As Pfizer kills failed PhIII programs for Bavencio, where do they go from here in R&D?

5 years ago

Voyager bags a 'transformational' $1.8B gene therapy pact with Neurocrine

5 years ago

Disgraced at Vertex, Ian Smith’s career implosion ends with swift exile from biotech boards

5 years ago

Alexander Hardy tapped to head back to South San Francisco as the next CEO at Genentech

5 years ago

First page Previous page 209 210 211212213 214 215 Next page Last page